September 4, 2007

Takeda Pharmaceutical Company Limited

Takeda Settles a Lawsuit over Remuneration for Employee Invention Regarding an Anti-prostate Cancer and Anti-endometriosis Drug, Leuplin^®

September 4, 2007, Osaka, Japan --- Takeda Pharmaceutical Company Limited ("Takeda") announced today that, following the advisory by Judges, it has settled a lawsuit claiming remuneration for employee inventions, regarding formulation patents covering "the sustained release formulation of Leuprorelin acetate (marketed under the brand name of "Leuplin" in Japan)", a treatment for prostate cancer and endometriosis, originated by Takeda. That lawsuit was brought against Takeda before the Tokyo District Court in October 2004 and December 2005 by plaintiffs who alleged that they had inherited the right to claim remuneration of the employee inventions.

The plaintiffs have claimed in the lawsuit payment of ¥1.5 billion as an initial part of remuneration for the employee inventions regarding formulation patents for Leuplin. In the settlement proposed by the Tokyo District Court seeking the whole solution of the dispute, it is stipulated that Takeda shall pay ¥37.59 million, including interest, in settlement of all employee inventions, including foreign patents and know-how as well, of an anonymous former employee who was one of the inventors of the patents in dispute.

About Takeda

Takeda, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan, and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

# # #